Efficacy and Safety of Topical Corticosteroids for Management of Oral Chronic Graft versus Host Disease

Table 2

The evidence table including study design, interventions, outcomes, level of evidence, and grade of recommendation.

Study	Quality assessment		Number of patients	Drug properties				Clinical response (efficacy)				Safety %
	Level	Grade		Drug	Conc.	Dose		Average time for best results (D)	Average mOMRS reduction (%)	Patients with mOMRS improvement (%)	VAS red. (%)	Side effects %
						mL	t/d
Clobetasol
Noce et al. [7]	1b	A	14	Oral rinse	0.5	5	3	28	50	85	44.6	7
Dexamethasone
Noce et al. [7]	1b	A	18	Oral rinse	0.01	5	3	28	50	33	29.7	5.5
Park et al. [8]	2b	B	24	Oral rinse	0.01	10	3-4	28	27.2	29.1	28.5	16.6
Wolff et al. [9]	4	C	16	Oral rinse	0.01	NR	NR	28	NR	68.7	NR	NR
Budesonide
Park et al. [8]	2b	B	26	Oral rinse	0.03	5–10	3–6	28	50	53.8	37.5	19
Elad et al. [10]	2b	B	18	Oral rinse	0.03	10	2-3	45.5	70	70	70	50
Sari et al. [9]	4	C	12	Oral rinse	0.03	10	3	28	66.6	83.3	54.4	16.6
Elad et al. [12]	4	C	12	Oral rinse	0.06	5	2-3	54	UC	100	UC	8

RCT: randomized clinical trial, pro-cohort: prospective cohort, Retro. Cohort: retrospective cohort, UC: unclear, and NR: not reported.